采用简化MRI筛查肝癌
本文综述了简化MRI(AMRI)用于肝细胞癌(HCC)筛查的现状。现行指南推荐肝硬化及慢性乙型肝炎高危人群每半年行肝脏超声(可联合血清甲胎蛋白)筛查,但该策略对早期肿瘤敏感性欠佳,尤其在肥胖患者中。AMRI通过有限序列采集(≤10分钟)可能提高时间与成本效益及准确性,但现有研究多为回顾性模拟、样本量较小且人群不具代表性,尚缺乏纵向研究直接比较不同AMRI方案或AMRI与超声。
要点
- 现行HCC筛查推荐每半年肝脏超声(可联合血清甲胎蛋白),但对早期肿瘤敏感性欠佳。
- AMRI为有限序列采集(≤10分钟),理论优势包括提高时间与成本效益及准确性。
- 现有AMRI研究多为回顾性模拟、样本量较小且人群不具代表性,需谨慎解读。
核心结论
- AMRI在患者层面的检出结果令人鼓舞,但已发表研究应谨慎解读。
- 尚无纵向研究直接比较不同AMRI方案或AMRI与超声。
- 可能单一方案不适用于所有患者,策略应依据HCC风险、AMRI成本与可及性量身定制。
- 多项试验正在进行以评估这些问题。
研究设计与样本
- 本文为综述,检索并汇总已发表的AMRI用于HCC筛查的研究。
- 多数研究为模拟设计,回顾性审阅接受完整MRI检查人群中的部分序列。
主要发现
- AMRI理论获益包括采集时间缩短(≤10分钟)、较常规MRI改善时间与成本效益、准确性优于超声。
- 已发表研究多来自亚洲团队,高危人群与西方人群不同。
- 现有研究纳入人群不具筛查人群代表性,且样本量相对较小。
关键数值与推荐
- 现行HCC筛查推荐:肝硬化及慢性乙型肝炎感染亚组患者每半年行肝脏超声(联合或不联合血清甲胎蛋白)。
- AMRI可采集的序列包括T1加权、T2加权和弥散加权成像(DWI),联合或不联合对比剂给药。
局限性
- 多数研究为模拟设计,回顾性审阅接受完整MRI检查人群中的部分序列。
- 研究人群相对较小且不具筛查人群代表性。
- 多数研究由亚洲团队发表,高危人群与西方人群不同。
- 尚无纵向研究直接比较不同AMRI方案或AMRI与超声。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current recommendations for the surveillance of HCC are based on the semiannual liver ultrasound (with or without serum alpha-fetoprotein) in patients with cirrhosis and in subgroups with chronic hepatitis B infection. However, the sensitivity of this strategy is suboptimal for the detection of early-stage tumors, especially in obese patients, due to interoperator variability and poor adherence. The detection rate of focal liver lesions is excellent with MRI, making it the best alternative candidate for surveillance. However, performing a full contrast-enhanced MRI is unrealistic because of limited availability and health economics. Abbreviated MRI (AMRI) corresponds to the acquisition of a limited number of sequences with a high detection rate. The theoretical benefits of AMRI are a reduced acquisition time (≤10 min) with improved time-effectiveness and cost-effectiveness compared with conventional MRI, and greater accuracy than ultrasound. Numerous protocols may be performed, including T1-weighted, T2-weighted, and DWI sequences, with or without contrast administration. Although published studies report promising per-patient results, they should be interpreted with caution. Indeed, most studies were simulated, retrospectively reviewing a subset of sequences in relatively small populations who underwent a full MRI. They also included groups that were not representative of screening populations. In addition, most were published by Asian groups, with at-risk populations that were different from Western populations. There are no existing longitudinal studies that directly compare the different AMRI approaches or AMRI to ultrasound. Finally, it is possible that 1 approach will not fit all patients and that strategies should be tailored to the risk of HCC, in particular in relation to the cost and availability of AMRI. Several trials are ongoing to evaluate these questions.
引用
- Ronot M, Nahon P, Rimola J, et al. Screening of liver cancer with abbreviated MRI. Hepatology. 2023. PMID: 36896975. doi:10.1097/HEP.0000000000000339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。